SingaporeTuberculosis profile
Population  2017 5.7 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.051 (0.038–0.066) 0.89 (0.66–1.1)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.11 (0.07–0.15)
Incidence  (includes HIV+TB) 2.7 (2.3–3.1) 47 (40–54)
Incidence (HIV+TB only) 0.039 (0.033–0.046) 0.69 (0.58–0.8)
Incidence (MDR/RR-TB)** 0.045 (0.025–0.069) 0.78 (0.44–1.2)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.12 (0.095–0.15) 0.93 (0.72–1.1) 1.1 (0.84–1.3)
Males 0.14 (0.1–0.17) 1.5 (1.1–1.8) 1.6 (1.3–2)
Total 0.26 (0.22–0.3) 2.4 (2–2.8) 2.7 (2.3–3.1)
TB case notifications, 2017  
Total cases notified 2 333
Total new and relapse 2 329
          - % tested with rapid diagnostics at time of diagnosis 52%
          - % with known HIV status 90%
          - % pulmonary 85%
          - % bacteriologically confirmed among pulmonary 62%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.02 (0.02–0.03)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 31 1%
          - on antiretroviral therapy    
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  33
(19–47)
Estimated % of TB cases with MDR/RR-TB 1.5% (0.89–2.4) 3.6% (0.74–10)  
% notified tested for rifampicin resistance 60% 66% 1 400
MDR/RR-TB cases tested for resistance to second-line drugs   19
Laboratory-confirmed cases MDR/RR-TB: 20, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 18, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 79% 2 435
Previously treated cases, excluding relapse, registered in 2016 75% 4
HIV-positive TB cases registered in 2016 82% 34
MDR/RR-TB cases started on second-line treatment in 2015 38% 13
XDR-TB cases started on second-line treatment in 2015   0
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment <1%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
> 100%
TB financing, 2018  
National TB budget (US$ millions) 16
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2019-09-24 Data: www.who.int/tb/data